Press releases
Interim report July 1 – September 30, 2019
24 October, 2019By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. First Quarter Summary (July – September 2019) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
Report from the annual general meeting in DexTech Medical AB on 17 October 2019
17 October, 2019Today, October 17, 2019, the Annual General Meeting of DexTech Medical AB was held. Below is a summary of the decisions that were made. All decisions were made with the […]
Promising follow-up results from DexTech’s Phase IIb study for OsteoDex
14 October, 2019The company’s phase IIb study for the treatment of advanced prostate cancer i.e. castration resistant metastatic prostate cancer (mCRPC), can report promising follow-up results as of October 14. Patients are […]
Dextech Medical AB Annual report 180701 – 190630
19 September, 2019Download annual report below. Dextech Annual Report 180701-190630
Report for DexTechs phase IIb-study for OsteoDex is ready
6 December, 2018OsteoDex, the company ́s phase 2b-project for treatment of advanced prostate cancer, mCRPC, is reported. The study is titled “A randomised, double-blind, dose-finding, repeat dose Phase II multicentre study of […]
First result from DexTechs phase IIb-study on OsteoDex
4 October, 2018OsteoDex, the company’s phase 2b-project for treatment of advanced prostate cancer, castration resistant prostate cancer (CRPC), is finished and the first results can be reported. The study has the title […]
Positive first results in DexTechs phase IIb-study for OsteoDex
9 February, 2017The study has the title “A randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and […]
DexTech closes research agreement on glycosylation technology
2 November, 2015Press release 2015-11-02 DexTech Medical AB, 556664-6203 DexTech closes research agreement on glycosylation technology DexTech announced today that Roche and DexTech have signed a research agreement with the aim to […]